These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 16052580)

  • 1. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.
    Wilkes MR; Sereika SM; Fertig N; Lucas MR; Oddis CV
    Arthritis Rheum; 2005 Aug; 52(8):2439-46. PubMed ID: 16052580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.
    Labirua-Iturburu A; Selva-O'Callaghan A; Martínez-Gómez X; Trallero-Araguás E; Labrador-Horrillo M; Vilardell-Tarrés M
    Clin Exp Rheumatol; 2013; 31(3):436-9. PubMed ID: 23465087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
    Yoshifuji H; Fujii T; Kobayashi S; Imura Y; Fujita Y; Kawabata D; Usui T; Tanaka M; Nagai S; Umehara H; Mimori T
    Autoimmunity; 2006 May; 39(3):233-41. PubMed ID: 16769657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort.
    Chua F; Higton AM; Colebatch AN; O'Reilly K; Grubnic S; Vlahos I; Edwards CJ; Kiely PD
    Rheumatology (Oxford); 2012 Oct; 51(10):1870-6. PubMed ID: 22763991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is tacrolimus effective for treating antisynthetase-associated interstitial lung disease?
    Bongartz T; Ryu JH; Matteson EL
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):80-1. PubMed ID: 16932636
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies.
    Dugar M; Cox S; Limaye V; Blumbergs P; Roberts-Thomson PJ
    Intern Med J; 2011 Sep; 41(9):674-9. PubMed ID: 20059602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease.
    Hirakata M; Suwa A; Nagai S; Kron MA; Trieu EP; Mimori T; Akizuki M; Targoff IN
    J Immunol; 1999 Feb; 162(4):2315-20. PubMed ID: 9973509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
    Zhan X; Yan W; Wang Y; Li Q; Shi X; Gao Y; Ye Q
    BMC Pulm Med; 2021 Feb; 21(1):57. PubMed ID: 33579248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two cases of interstitial pneumonia with anti-PL-12 (alanyl tRNA synthetase) antibodies].
    Satoh S; Hirakata M; Suwa A; Mimori T; Inada S; Akizuki M
    Ryumachi; 1996 Dec; 36(6):862-8. PubMed ID: 9122826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease.
    D'Cruz D; Keser G; Khamashta MA; Direskeneli H; Targoff IN; Miller F; Hughes GR
    J Rheumatol; 2000 Jan; 27(1):161-4. PubMed ID: 10648033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias.
    Watanabe K; Handa T; Tanizawa K; Hosono Y; Taguchi Y; Noma S; Kobashi Y; Kubo T; Aihara K; Chin K; Nagai S; Mimori T; Mishima M
    Respir Med; 2011 Aug; 105(8):1238-47. PubMed ID: 21514811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.
    Cavagna L; Caporali R; Abdì-Alì L; Dore R; Meloni F; Montecucco C
    J Rheumatol; 2013 Apr; 40(4):484-92. PubMed ID: 23418387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy.
    Stone KB; Oddis CV; Fertig N; Katsumata Y; Lucas M; Vogt M; Domsic R; Ascherman DP
    Arthritis Rheum; 2007 Sep; 56(9):3125-31. PubMed ID: 17763431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
    Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
    Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-PL-7, anti-PL-12, and other anti-aminoacyl tRNA synthetase antibodies].
    Hirakata M
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():555-9. PubMed ID: 20942128
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical implications of autoantibody screening in patients with autoimmune myositis.
    Ghirardello A; Zampieri S; Tarricone E; Iaccarino L; Bendo R; Briani C; Rondinone R; Sarzi-Puttini P; Todesco S; Doria A
    Autoimmunity; 2006 May; 39(3):217-21. PubMed ID: 16769655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset.
    Tillie-Leblond I; Wislez M; Valeyre D; Crestani B; Rabbat A; Israel-Biet D; Humbert M; Couderc LJ; Wallaert B; Cadranel J
    Thorax; 2008 Jan; 63(1):53-9. PubMed ID: 17557770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases.
    Hervier B; Wallaert B; Hachulla E; Adoue D; Lauque D; Audrain M; Camara B; Fournie B; Couret B; Hatron PY; Dubucquoi S; Hamidou M
    Rheumatology (Oxford); 2010 May; 49(5):972-6. PubMed ID: 20156976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
    Franzolini N; Quartuccio L; De Marchi G; De Vita S
    Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.